Quarterly reviews of the companies I own and the ones I’m considering, with dated updates when important evidence changes.
53completed earnings reviews40catalyst check-ins
MOST RECENT FIRST
Reports & check-ins
Ordered by release date. Catalyst updates are marked separately.
CATALYST CHECK-IN · REDEFINE 9 and ObesityWeek clinical update
Released Nov 14, 2026 · Reviewed Nov 16, 2026
Lower-dose efficacy adds flexibility, not a separate valuation premium.
Reported evidence
In the 309-participant REDEFINE 9 trial, CagriSema 1.7/1.7mg and 1.0/1.0mg produced 20.7% and 21.0% estimated weight loss at 68 weeks under the adherence-based efficacy estimand, versus 2.0% placebo. Treatment-regimen estimates were 19.4% and 18.6% versus 4.6%. This strengthens dose-flexibility evidence for the pipeline, not a finding that the lower dose is superior, an approved product or higher recurring earnings. The trial was not powered to compare the two doses.
What to watch
November 15's 25.4% loss is observed on-treatment data among early responders, not the randomized overall REDEFINE 1 population or a new pivotal result. Adverse-event discontinuations in REDEFINE 9 were 2.9%/4.9% versus 4.9% placebo; this does not establish a cross-trial tolerability advantage. Company-reported food-noise associations are retrospective, persistence-selected and not causal proof. The specific company releases/tables were reviewed; the full journal article and broad dynamic news/calendar indexes were not independently completed.
Consider buying
Consider an exploratory entry around $41.63, inside the unchanged $36–42 range and near its upper end; prefer the lower half if net-pricing uncertainty increases. The buy case is the existing cash-generating franchise plus a credible stabilization path, not an assumption that CagriSema wins every competitor comparison. Waiting for a regulatory decision and 2027 pricing clarity could reduce uncertainty but miss a rerating. Persistent earnings erosion below the modeled path invalidates the entry case even inside the band.
Strengthened
Price versus opportunity
Retain fixed DKK 6.523/USD as a historical modeling convention and one ADR per B share. DKK 18/24/28 normalized EPS at 12×/16×/18× gives $33.11/$58.87/$77.27 bear/base/bull, excluding a separate pipeline premium. At $41.63, base is about 41% higher and ordinary bear 20% lower; DKK 14 at 10× is $21.46, about 48% lower, not a floor. Base DKK 24 still needs approximately DKK 315bn sales, 43% operating margin and 78% after-tax conversion on about 4.417bn shares, before financial items. No EPS, probability or multiple uplift follows automatically from these data.
Review price: $41.63 · Nov 13, 2026 close
Current quarter versus prior quarter
Metric
Prior
Current
Change
Lower-dose phase 3 efficacy
No randomized lower-dose results in latest Q3 review
20.7%/21.0% vs 2.0% placebo, efficacy estimand
Supportive; no powered cross-dose superiority
Treatment-regimen estimate
Adherence-only headline would be incomplete
19.4%/18.6% vs 4.6% placebo
Includes discontinuation/rescue-treatment estimand
Early-response subgroup
Overall REDEFINE 1 evidence already known
25.4% among early responders, observed on-treatment
Post hoc selection, not new all-participant efficacy
No new financial guidance or exact regulatory-action date was announced. The company still expects a U.S. CagriSema decision in Q4 2026; it remains investigational and not U.S.-approved in these releases. Broad Q4 timing and conference attendance do not authorize daily checks or an end-of-conference follow-up.
Management language
These are clinical releases, not a new earnings call. The sponsor appropriately distinguishes efficacy from treatment-regimen estimands and calls the early-responder work hypothesis-generating. My inference is improved dose flexibility and commercial optionality, not proof of superior outcomes versus higher-dose CagriSema or competitors. The November 9 6-K is routine repurchase execution, not a new buyback authorization or operating outlook change.
Next checkpoint
Actual regulatory action when announced, product-label and reimbursement economics, and Q4/2027 net-pricing/cash performance. The November 13 close predates weekend data; do not present it as a post-readout reaction or claim the data are priced in.
Milestone timing
Milestone
Previously
Now
Movement
Lower-dose CagriSema data
Awaited trial evidence
November 14 randomized REDEFINE 9 data released
Completed; no obsolete follow-up retained
U.S. CagriSema action
Q4 2026 expected
Same broad window
No fixed decision date verified
2027 earnings bridge
Net pricing, cash and launch economics unresolved
Not answered by clinical data
Financial checkpoint remains essential
What improved
Randomized lower-dose evidence broadens the plausible dosing toolkit.
The sponsor reports meaningful weight reduction under both estimands, with important design and tolerability qualifications.